Clin Osteol 2012; 17(1): 8-13

Vascular calcifications in patients with chronic kidney failure: epidemiology, diagnosis and possible therapyReview articles

F. Švára

Vascular calcifications (VCs) are significantly more frequent in patients with chronic kidney disease than in the normal population. The high incidence of VCs and their progression are among factors causing high morbidity and mortality in these patients. The dia­ gnosis of VCs is most frequently based on radiological and ultrasound examinations. However, the methods used for quantifying the incidence of VCs are rather varied. Medications used to treat CKD-MBD may both decelerate and acceler

Keywords: vascular calcifications, chronic kidneyfailure, phosphate binders, vitamin D, calcimimetics

Published: June 11, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Švára F. Vascular calcifications in patients with chronic kidney failure: epidemiology, diagnosis and possible therapy. Osteologický bulletin. 2012;17(1):8-13.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nitta K, Akiba T, Suzuki K, et al. Assessment of coronary artery calcification hemodialysis patients using multi-detector spiral CT scan. Hypertens Res 2004; 27:527-533. Go to original source...
    2. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long­ term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997;77(1):37. Go to original source...
    3. Meema HE, Oreopoulos DG. Morphology, progression, and regression of arterial and periarterial calcifications in patients with end-stage renal disease. Ra 1986;158(3):671. Go to original source...
    4. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New in­ dices to classify location, severity and progression of calcific lesions i minal aorta: a 25-years follow-up study. Atherosclerosis 1997;132:245-250. Go to original source...
    5. Ogawa T, Ishida H, Matsuda N et al. Simple evaluation of aortic arch calcifica on by chest radiography in hemodialysis patients. Hemodial Int 2009;13:301-306. Go to original source...
    6. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Goncalves M, Negrao AP. A simple vascular calcification score predicts cardiovascular risk in haemodialy­ sis patients. Nephrol Dial Transplant 2004;19:1480-1488. Go to original source...
    7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; Suppl 113:S1-S130.
    8. Mieres JH, Shaw LJ, Arai A et al. Role of noninvasive testing in the clinical evaluation of men with suspected coronary artery disease: Circulation. 2005; 111(5):682.
    9. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomogra­ phy. J Am Coll Cardiol 1990;15:827-832. Go to original source...
    10. Callister TQ, Cooil B, Raya SP, Lippolis NJ, Russo DJ, Raggi P. Coronary ar disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology 1998;208:807-814. Go to original source...
    11. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998; 13:2037-2040. Go to original source...
    12. Schlieper G, Aretz A, Verberckmoes SC et al. Ultrastruc Calcifications in Uremia. J Am Soc Nephrol 2010;21:689-696. Go to original source...
    13. P^nuccio V, Tripepi R, Tripepi G et al. Heart valve calcifications, surviv cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2004;43:479-484. Go to original source...
    14. Russo D, Corrao S, Miranda I et al. Progression of coronary artery calcification predialysis patients. Am J Nephrol 2007;27:152-158. Go to original source...
    15. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on co­ ronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815-1824. Go to original source...
    16. Naves M, Díaz-López JB, Gómez C, Rodríguez-Rebollar A, Rodríguez-García M, Cannata-Andía JB. The effect of vertebral fracture as a risk factor for osteoporo­ tic fracture and mortality in a Spanish population. Osteoporosis International 2011;14(6):520-524. Go to original source...
    17. Sigrist MK, Taal MW, Bungay P et al. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007;2: 1241-1248. Go to original source...
    18. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on co­ ronary calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815-1824. Go to original source...
    19. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end­ stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740. Go to original source...
    20. Nitta, K. Vascular Calcification in Patients With Chronic Kidney Disease. Thera­ peutic Apheresis and Dialysis. doi: 10.1111/j.1744-9987.2011.00979.x
    21. Wang AY, Wang M, Woo J et al. Cardiac valve calcification as an important pre­ dictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14:159-168. Go to original source...
    22. Hernandez D, Rufino M, Bartolomei S et al. Clinical impact of preexisting vascu­ lar calcifications on mortality after renal transplantation. Kidney Int 2005;67: 2015-2020. Go to original source...
    23. Sigrist MK, Taal MW, Bungay P et al. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007;2: 1241-1248. Go to original source...
    24. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478. Go to original source...
    25. Chertow GM, Raggi P, Chasan-Taber S et al. Determinants ofprogressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19(6):1489. Go to original source...
    26. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group Sevelamer atte­ nuates the progression of coronary and aortic calcification in hemodialysis pa­ tients. Kidney Int 2002;62(1):245. Go to original source...
    27. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevela­ mer hydrochloride on the calcium x phosphate product and lipid profile of hae­ modialysis patients. Nephrol Dial Transplant 1999;14:2907. Go to original source...
    28. Burke SK, Dillon MA, Hemken DE et al. Metaanalysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 2003;10:133. Go to original source...
    29. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on co­ ronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815-1824. Go to original source...
    30. Qunibi W, Moustafa M, Muenz LR et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemo­ dialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-965. Go to original source...
    31. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance he­ modialysis patients. Am Heart J 2005;149(5):820. Go to original source...
    32. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72: 1130-1137. Go to original source...
    33. St Peter WL, Liu J, Weinhandl E et al. A comparison of sevelamer and calcium­ based phosphate binders on mortality, hospitalization, and morbidity in hemodia­ lysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51:445-454. Go to original source...
    34. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hy­ perphosphatemia: safety and efficacy in chronic maintenance hemodialysis pa­ tients. Clin Nephrol 2006;65:191-202. Go to original source...
    35. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005;100:c8-19. Go to original source...
    36. Malluche HH, Siami GA, Swanepoel C et al. Improvements in renal osteodys­ trophy in patiens treated with lanthanum carbonate for two years. Clin Nephrol 2008;70:284-295.
    37. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcifi­ cation with lanthanum carbonate versus calcium-based phosphate binders in hae­ modialysis: A pilot randomized controlled trial. Nephrology 2011;16(3):290-298. Go to original source...
    38. Tukaj C, Kubasik-Juraniec J, Kraszpulski M. Morphological changes of aortal smooth muscle cells exposed to calcitriol in culture. Med Sci Monit 2000; 6(4):668.
    39. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990;38(5):931. Go to original source...
    40. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long­ term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997;77(1):37. Go to original source...
    41. Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98(13):1302. Go to original source...
    42. Nakane M, Fey TA, Dixon DB et al. Differential effects of Vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2006;98:72-77. Go to original source...
    43. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25(OH)2D2 and 1alpha-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats. Kidney Int 2002;62:1277-1284. Go to original source...
    44. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Pricalcitol versus cal­ citriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63(4):1483. Go to original source...
    45. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vit D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72(6):709. Go to original source...
    46. Wu-Wong JR, Melnick J. Vascular calcifications in chronic k vitamin D receptor. Curr Opin Investig Drugs 2007;8(3):237-247. Go to original source...
    47. Stenvinkel P, Ketteler M, Girndt M et al., IL-10, IL-6, and TNF-a: Centr in the altered cytokine network of uremia - The good, the bad, and the ugly. Kidney Int 2005;67:1216-1233. Go to original source...
    48. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardio­ vascular mor 361:827-833.
    49. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-rela quality of life in secondary hyperparathyroidism. Kidney Int 2005;68(4):1793. Go to original source...
    50. Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, Liu J, St Pster Cinacalcet hydrochloride treatment significantly improves all-cause and cardio­ vascular survival in a large cohort of haemodialysis patients. Kidney Int 2010;78(6):578. Go to original source...
    51. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalc and acalcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73:300-307. Go to original source...
    52. Floege J, Raggi P, Block GA et al. Study design and subject baseline characte­ ristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2010;25(6):1916-1923. Go to original source...
    53. Raggi P, Chetrow GM, Torres PU et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcifica­ tion in patients on haemodialysis. Nephrol Dial Transplant 2011;26:1327-1339. Go to original source...
    54. Moe SM, O'Neill KD, Reslerova M, Fineberg N, Persohn S, Meyer CA Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004;19(9):2387. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.